基础医学与临床 ›› 2021, Vol. 41 ›› Issue (7): 1056-1059.

• 短篇综述 • 上一篇    下一篇

间充质干细胞治疗肺纤维化的研究进展

陈民佳1,汪晓月2,陈客宏2,陆红祥1   

  1. 1. 中国人民解放军陆军特色医学中心
    2. 陆军军医大学第三附属医院
  • 收稿日期:2020-08-04 修回日期:2020-12-07 出版日期:2021-07-05 发布日期:2021-06-17
  • 通讯作者: 陆红祥 E-mail:18908373382@163.com
  • 基金资助:
    视神经诱变蛋白optineurin在糖尿病肾病肾小管细胞应激性衰老中的作用和机制

Research progress of mesenchymal stem cells in the treatment of pulmonary fibrosis

  • Received:2020-08-04 Revised:2020-12-07 Online:2021-07-05 Published:2021-06-17

摘要: 肺纤维化尚无有效的治疗药物和干预方法。间充质干细胞 (MSCs) 治疗特发性肺纤维化、放射性肺纤维化等类型肺纤维化的机制有多种,包括通过旁分泌作用,释放白细胞介素-1受体拮抗剂,抑制白细胞介素-1和肿瘤坏死因子-α的表达,抵抗组织炎性反应;增加肝细胞生长因子(HGF)信号转导,抑制PI3K/AKT/mTOR活化,降低肺泡II上皮细胞(ATII)的上皮间充质转化(EMT),减轻肺组织细胞凋亡和纤维化等等,促进组织抗炎、抗纤维化等功能,延缓器官纤维化。本文期望能够为MSCs治疗器官纤维化提供研究思路。

关键词: 间充质干细胞, 治疗, 肺纤维化

Abstract: There is no effective therapeutic drug and intervention method for pulmonary fibrosis. There are many mechanisms of mesenchymal stem cell in the treatment of idiopathic pulmonary fibrosis, radiation pulmonary fibrosis and other types of pulmonary fibrosis, including paracrine, releasing leukocyte mediator-1 receptor antagonist, inhibiting the expression of interleukin-1 and tumor necrosis factor-α, and resisting tissue inflammation. Increase hepatocyte growth factor signal transduction, inhibit PI3K/AKT/mTOR activation, reduce epithelial mesenchymal transformation in alveolar II epithelial cells, reduce lung tissue apoptosis and fibrosis, promote tissue anti-inflammatory and anti-fibrosis, and delay organ fibrosis. This paper is expected to provide research ideas for the treatment of organ fibrosis with MSCs.

Key words: Mesenchymal Stem Cells, therapy, pulmonary fibrosis

中图分类号: